balance equationreview2021-12-31
Difference 20600000 exceeds tolerance 20385400.000. Presentation or filing-vintage differences need review.
Revenue
$13.95B
Fiscal year ended 2025-12-31Operating income
$1.38B
Fiscal year ended 2025-12-31Free cash flow
$1.21B
Fiscal year ended 2025-12-31LABCORP HOLDINGS INC. (LH) reported revenue of $13.95B and net income of $876.50M for the fiscal year ended 2025-12-31. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from LABCORP HOLDINGS INC.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Services-Medical Laboratories.
Income
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $13.95B | $13.01B | $12.16B | $11.86B | $13.14B | $13.98B | $11.55B | $11.33B | $10.31B | $9.55B |
| Cost of revenue | $9.94B | $9.38B | $8.80B | $8.16B | $8.14B | $9.03B | $8.30B | $8.16B | $7.22B | $6.70B |
| Gross profit | $4.01B | $3.62B | $3.36B | $3.71B | $4.99B | $4.95B | $3.25B | $3.18B | $3.09B | $2.85B |
| Operating income | $1.38B | $1.09B | $725.60M | $1.44B | $3.05B | $2.45B | $1.33B | $1.33B | $1.31B | $1.27B |
| Net income | $876.50M | $746.00M | $418.00M | $1.28B | $2.38B | $1.56B | $823.80M | $883.70M | $1.23B | $711.80M |
| Research & development | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Weighted-average diluted shares | shares 83.80M | shares 84.40M | shares 87.60M | shares 91.60M | shares 97.50M | shares 98.00M | shares 98.60M | shares 102.60M | shares 103.90M | shares 104.30M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | $229.80M | $212.40M | $188.50M | $233.90M | $690.00M | $662.10M | $280.00M | $384.40M | -$155.40M | $360.70M |
| Diluted EPS | $10.46 | $8.84 | $4.77 | $13.97 | $24.39 | $15.88 | $8.35 | $8.61 | $11.81 | $6.82 |
| Selling, general & administrative | $2.22B | $2.23B | $2.02B | $1.76B | $1.69B | $1.73B | $1.62B | $1.57B | $1.50B | $1.35B |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $532.30M | $1.52B | $536.80M | $320.60M | $1.47B | $1.32B | $337.50M | $426.80M | $316.60M | $433.60M |
| Total assets | $18.39B | $18.38B | $16.73B | $20.16B | $20.39B | $20.07B | $18.05B | $16.19B | $16.67B | $14.25B |
| Current assets | $4.02B | $4.81B | $3.77B | $4.62B | $5.33B | $5.13B | $2.98B | $2.84B | $2.73B | $2.48B |
| Total liabilities | $9.76B | $10.31B | $8.83B | $10.04B | $10.09B | $10.61B | $10.46B | $9.19B | $9.85B | $8.73B |
| Current liabilities | $2.82B | $3.33B | $3.23B | $3.08B | $2.78B | $3.08B | $2.66B | $1.88B | $2.19B | $1.83B |
| Total equity incl. NCI | $8.62B | $8.05B | $7.88B | $10.10B | $10.27B | $9.44B | $7.64B | $7.05B | $6.80B | $5.52B |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $534.70M | $493.20M | $474.60M | $470.60M | $401.40M | $423.20M | $244.70M | $237.30M | $227.20M | $205.20M |
| Accounts receivable | $2.10B | $1.94B | $1.91B | $1.79B | $2.26B | $2.48B | $1.54B | $1.47B | $1.53B | $1.33B |
| Goodwill | $6.79B | $6.37B | $6.14B | $6.12B | $5.89B | $7.75B | $7.86B | $7.36B | $7.40B | $6.42B |
| Long-term debt | $5.08B | $5.33B | $4.05B | $5.04B | $5.42B | $5.42B | $5.79B | $5.99B | $6.34B | $5.30B |
| Accounts payable | $840.80M | $875.80M | $827.50M | $852.20M | $621.30M | $638.90M | $632.30M | $634.60M | $573.90M | $508.40M |
Cash flow
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $1.64B | $1.59B | $1.33B | $1.96B | $3.11B | $2.14B | $1.44B | $1.31B | $1.50B | $1.20B |
| Capital expenditures | $434.50M | $489.90M | $453.60M | $429.30M | $421.50M | $381.70M | $400.20M | $379.80M | $312.90M | $278.90M |
| Investing cash flow | -$1.19B | -$1.37B | -$1.17B | -$1.65B | -$884.60M | -$643.20M | -$1.28B | $206.70M | -$2.23B | -$795.70M |
| Financing cash flow | -$1.46B | $779.90M | -$59.30M | -$1.32B | -$2.07B | -$517.40M | -$252.70M | -$1.39B | $593.20M | -$671.00M |
| Net change in cash | -$986.40M | $981.90M | $106.80M | -$1.04B | $151.90M | $983.30M | -$89.30M | $110.20M | -$116.90M | -$282.80M |
| Stock-based compensation | $125.80M | $116.70M | $128.70M | $116.80M | $132.90M | $111.70M | $107.00M | $91.60M | $109.70M | $109.60M |
| Common dividends paid | $240.70M | $243.10M | $254.00M | $195.20M | $0 | $0 | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | $450.00M | $250.10M | $1.00B | $1.10B | $1.67B | $100.00M | $450.00M | $700.00M | $338.10M | $43.90M |
| Depreciation & amortization | $681.10M | $643.50M | $577.30M | $537.20M | $577.00M | $624.70M | $577.20M | $552.10M | $533.20M | $499.20M |
Derived
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $1.21B | $1.10B | $874.10M | $1.53B | $2.69B | $1.75B | $1.04B | $925.60M | $1.19B | $918.20M |
| Gross margin | 28.8% | 27.9% | 27.7% | 31.3% | 38.0% | 35.4% | 28.1% | 28.0% | 30.0% | 29.9% |
| Operating margin | 9.9% | 8.4% | 6.0% | 12.1% | 23.2% | 17.5% | 11.5% | 11.7% | 12.7% | 13.3% |
| FCF margin | 8.6% | 8.4% | 7.2% | 12.9% | 20.5% | 12.5% | 9.0% | 8.2% | 11.5% | 9.6% |
| SBC / revenue | 0.9% | 0.9% | 1.1% | 1.0% | 1.0% | 0.8% | 0.9% | 0.8% | 1.1% | 1.1% |
| Current ratio | 1.42x | 1.44x | 1.17x | 1.50x | 1.92x | 1.66x | 1.12x | 1.51x | 1.25x | 1.36x |
| Revenue YoY growth | 7.2% | 7.0% | 2.5% | -9.7% | -6.0% | 21.0% | 2.0% | 9.9% | 7.9% | Unavailable |
| Net margin | 6.3% | 5.7% | 3.4% | 10.8% | 18.1% | 11.1% | 7.1% | 7.8% | 11.9% | 7.5% |
| R&D / revenue | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| CapEx / revenue | 3.1% | 3.8% | 3.7% | 3.6% | 3.2% | 2.7% | 3.5% | 3.4% | 3.0% | 2.9% |
| Long-term debt / equity | 0.59x | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open LH in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-04View SEC filing
10-K · Filed 2026-02-24View SEC filing
10-Q · Filed 2025-10-31View SEC filing
10-Q · Filed 2025-08-01View SEC filing
10-Q · Filed 2025-04-29View SEC filing
Reconciliation checks needing review
5 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
balance equationreview2020-12-31
Difference 20700000 exceeds tolerance 20071700.000. Presentation or filing-vintage differences need review.
balance equationreview2019-12-31
Difference 56800000 exceeds tolerance 18046400.000. Presentation or filing-vintage differences need review.
balance equationreview2018-12-31
Difference 57800000 exceeds tolerance 16185300.000. Presentation or filing-vintage differences need review.
balance equationreview2017-12-31
Difference 20800000 exceeds tolerance 16673000.000. Presentation or filing-vintage differences need review.